Deimination of the myelin basic protein decelerates its proteasome-mediated metabolism by Kuzina E. et al.
Doklady Biochemistry and Biophysics 2016 vol.469 N1, pages 277-280
Deimination of the myelin basic protein decelerates its
proteasome-mediated metabolism
Kuzina E., Kudriaeva A., Glagoleva I., Knorre V., Gabibov A., Belogurov A.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2016, Pleiades Publishing, Ltd.Deimination of myelin basic protein (MBP) by peptidylarginine
deiminase (PAD) prevents its binding to the proteasome and decelerates its degradation by the
proteasome in mammalian cells. Potential anticancer drug tetrazole analogue of chloramidine 2,
at concentrations greater than 1 µM inhibits the enzymatic activity of PAD in vitro. The observed
acceleration of proteasome hydrolysis of MBP to antigenic peptides in the presence of PAD
inhibitor  may increase the efficiency of  lesion of  the central  nervous system by cytotoxic
lymphocytes in multiple sclerosis. We therefore suggest that clinical trials and the introduction
of  PAD inhibitors  in  clinical  practice  for  the  treatment  of  malignant  neoplasms should  be
performed only after a careful analysis of their potential effect on the induction of autoimmune
neurodegeneration processes.
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